Barbara Fleeman’s Story

Barbara Fleeman WomenHeart Champion; Support Group Facilitator Barbara grew up in Atlanta and moved back 6 years ago after spending 40 years building a successful career in entertainment consumer marketing/promotion.  She was always very active in her personal and professional life.  In 2013 she was diagnosed with severe pericarditis.  Over the following 18 months. She…

Read More

The Licensing of Academic Patents Contributed Up to $1.9 Trillion to the US Economy, Supported up to 6.5 Million Jobs in the last 25 Years New Report Highlights the Importance of Research and Public-Private Partnerships

The licensing of university and nonprofit research has made a significant contribution to US gross domestic product (GDP), industrial gross output, and jobs over the last 25 years and underscores the importance of basic and applied research to the US economy, as well as the demand for public-private partnerships. The findings are based on an…

Read More

Aruna Bio Announces Issuance of a New Composition Of Matter Patent Covering Neural Exosomes in Japan

Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that the Japan UPSC UENO Patent Office has issued a patent, No. 7075594, to Aruna Bio and the University of Georgia Research Foundation allowing broad claims on the composition of neural exosomes and their use as a therapeutic for…

Read More

Augusta University to launch new School of Public Health

Augusta University President Brooks A. Keel, PhD, has announced the creation of the School of Public Health, which will be a crucial tool in helping promote the health of populations in today’s rapidly changing environment. “As the state’s only public academic health center, it is our responsibility and our privilege to help ensure the health of…

Read More

Science Hill funding approved by Georgia General Assembly

Several UGA projects received financial support from Georgia lawmakers this session During the recent 2022 legislative session, state lawmakers voted to support the University of Georgia’s growing research enterprise by investing close to $49 million to complete the renovation of 186,000 square feet of laboratory space on a section of campus called Science Hill. The ongoing…

Read More

Cambium Co-Founders Receive “Start-Up of the Year” Award From Emory University’s Office of Tech Transfer

Approval in 2021 to begin Phase III studies on Elate Ocular® Biologic for Dry Eye Major Milestone Supporting Award Cambium Medical Technologies, a clinical stage company developing novel processed allogeneic platelets for therapeutic applications, announced today two co-founders were awarded “Start-Up of the Year” by Emory University’s Office of Technology Transfer. The award was one of…

Read More

Four Emory professors named to American Academy of Arts and Sciences

Four Emory University faculty members have been elected to the American Academy of Arts and Sciences, one of the nation’s oldest and most prestigious honorary societies and a leading center for independent policy research. Elected this year are: Carlos del Rio, MD, executive associate dean, Emory School of Medicine & Grady Health System; Leon L.…

Read More

Georgia Tech’s Paul Joseph Awarded Fulbright Specialist Grant to India

Paul Joseph, a principal research scientist in the Institute for Electronics and Nanotechnology (IEN) at Georgia Tech, has received a Fulbright Specialist Award to India from the Fulbright Foreign Scholarship Board. Joseph will spend two weeks at the Indian Institute of Information technology (IIIT) this summer helping to expand the nanotechnology curriculum and assisting with…

Read More

Saol Therapeutics Announces First Patient Dosed in Phase 2 RAISE Spasticity Trial Evaluating the Safety Profile of SL-1002 for Limb Spasticity

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the company’s Phase 2 RAISE Spasticity Trial.  SL-1002 is a novel, proprietary, nerve-blocking agent currently under development at Saol Therapeutics and is being evaluated in the RAISE Spasticity Trial.  The trial is a double-blind, placebo-controlled, single ascending-dose…

Read More